Floatz logo

Olaparib

Malignant Solid Neoplasms

Centre Leon BerardSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Malignant Solid Neoplasms cohort.

Asset / SponsorPhaseRating
Sorafenib
Centre Leon Berard
Phase 2CCC
Nilotinib
Centre Leon Berard
Phase 2CCC
Durvalumab
Centre Leon Berard
Phase 2CCC
Everolimus
Centre Leon Berard
Phase 2CCC
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER
Centre Leon Berard
Phase 2CCC
gw786034
Centre Leon Berard
Phase 2CCC
Lapatinib
Centre Leon Berard
Phase 2CCC

Same molecule, other indications

Olaparib is also rated in:

breast carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
fallopian tube serous adenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →